Treosulfan

Identification

Generic Name

Treosulfan

DrugBank Accession Number

DB11678

Background

Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.

Type

Small Molecule

Groups

Approved, Investigational

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Treosulfan (DB11678)

×

Close

Weight

Average: 278.29
Monoisotopic: 278.013009759

Chemical Formula

C₆H₁₄O₈S₂

Synonyms

• DIHYDROXYBUSULFAN
• OVASTAT
• Treosulfan

External IDs

• NSC-39069

Pharmacology

Indication

Not Available

Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:

Machine Learning

Data Science

Drug Discovery

Accelerate your drug discovery research with our fully connected ADMET dataset

Learn more

Associated Therapies

• HSCT conditioning therapy

Contraindications & Blackbox Warnings

Contraindications & Blackbox Warnings

With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.

Learn more

Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Reduce medical errors

and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.

Learn more

Reduce medical errors & improve treatment outcomes with our adverse effects data

Learn more

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Treosulfan.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Treosulfan.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Treosulfan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Treosulfan.

Improve patient outcomes

Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.

Learn more

Food Interactions

Not Available

Products

Comprehensive & structured drug product info

From application numbers to product codes, connect different identifiers through our commercial datasets.

Learn more

Easily connect various identifiers back to our datasets

Learn more

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Trecondi	Injection, powder, for solution	5 g	Intravenous	Medac Gesellschaft Für Klinische Spezialpräparate Mb H	2020-12-16	Not applicable
Trecondi	Injection, powder, for solution	1 g	Intravenous	Medac Gesellschaft Für Klinische Spezialpräparate Mb H	2020-12-16	Not applicable
Trecondi	Injection, powder, for solution	5 g	Intravenous	Medac Gesellschaft Für Klinische Spezialpräparate Mb H	2020-12-16	Not applicable
Trecondi	Injection, powder, for solution	1 g	Intravenous	Medac Gesellschaft Für Klinische Spezialpräparate Mb H	2020-12-16	Not applicable
Trecondyv	Powder	5 g / vial	Intravenous	Medexus Inc	Not applicable	Not applicable
Trecondyv	Powder	1 g / vial	Intravenous	Medexus Inc	Not applicable	Not applicable

Categories

ATC Codes

L01AB02 — Treosulfan

• L01AB — Alkyl sulfonates
• L01A — ALKYLATING AGENTS
• L01 — ANTINEOPLASTIC AGENTS
• L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Categories

• Acids
• Acids, Noncarboxylic
• Alcohols
• Alkanes
• Alkanesulfonates
• Alkanesulfonic Acids
• Alkylating Drugs
• Antineoplastic Agents
• Antineoplastic Agents, Alkylating
• Antineoplastic and Immunomodulating Agents
• Butylene Glycols
• Glycols
• Hydrocarbons, Acyclic
• Mesylates
• Noxae
• Sulfonic Acids
• Sulfur Acids
• Sulfur Compounds
• Toxic Actions

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as organosulfonic acid esters. These are esters of sulfonic acid, which have the general structure RS(=O)2OR' (R,R' = organyl, not H).

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Organic sulfonic acids and derivatives

Sub Class

Organosulfonic acids and derivatives

Direct Parent

Organosulfonic acid esters

Alternative Parents

Sulfonic acid esters / Sulfonyls / Methanesulfonates / Secondary alcohols / 1,2-diols / Organic oxides / Hydrocarbon derivatives

Substituents

1,2-diol / Alcohol / Aliphatic acyclic compound / Hydrocarbon derivative / Methanesulfonate / Organic oxide / Organic oxygen compound / Organooxygen compound / Organosulfonic acid ester / Organosulfur compound

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

methanesulfonate ester (CHEBI:82557)

Affected organisms

Not Available

Chemical Identifiers

UNII

CO61ER3EPI

CAS number

299-75-2

InChI Key

YCPOZVAOBBQLRI-WDSKDSINSA-N

InChI

InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1

IUPAC Name

(2S,3S)-2,3-dihydroxy-4-(methanesulfonyloxy)butyl methanesulfonate

SMILES

CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O

References

General References

1. EMA Summary of Product Characteristics: Trecondi (treosulfan) powder for solution for infusion [Link]

External Links

KEGG Compound

C19557

PubChem Compound

9882105

PubChem Substance

347828046

ChemSpider

8057780

RxNav

38508

ChEBI

82557

ChEMBL

CHEMBL455186

ZINC

ZINC000001671094

Wikipedia

Treosulfan

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Completed	Treatment	Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
3	Completed	Treatment	Ewing's Sarcoma	1
3	Completed	Treatment	Ovarian Cancer	1
3	Unknown Status	Treatment	Lymphoblastic Leukemia, Acute, Childhood	2
3	Unknown Status	Treatment	Melanomas	1
2	Active Not Recruiting	Treatment	Acute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Myelodysplastic Syndrome	1
2	Active Not Recruiting	Treatment	Acute myeloid leukaemia (in remission) / Chronic Myelomonocytic Leukemia / Minimal Residual Disease / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myelodysplastic/Myeloproliferative Neoplasms	1
2	Active Not Recruiting	Treatment	Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Transplant-Related Hematologic Malignancy	1
2	Active Not Recruiting	Treatment	Bone Marrow Failure Syndromes / Congenital Immunodeficiency / Haemoglobinopathies congenital / Inborn Errors of Metabolism	1
2	Active Not Recruiting	Treatment	Non-Neoplastic Hematologic and Lymphocytic Disorder	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, powder, for solution	Intravenous	1 G
Injection, powder, for solution	Intravenous	5 G
Powder	Intravenous	1 g / vial
Powder	Intravenous	5 g / vial
Powder, for solution

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	17.0 mg/mL	ALOGPS
logP	-1.5	ALOGPS
logP	-2.6	ChemAxon
logS	-1.2	ALOGPS
pKa (Strongest Acidic)	12.99	ChemAxon
pKa (Strongest Basic)	-3.5	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	127.2 Å2	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	51.98 m3·mol-1	ChemAxon
Polarizability	24.93 Å3	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

×

Improve patient outcomes

Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.

Learn more

Drug created on October 20, 2016 20:39 / Updated on February 21, 2021 18:53